IQVIA Launches Patient Portal
IQVIA has announced its launch of the IQVIA Patient Portal, a global web-based solution built on the Salesforce Health Cloud platform.
“Patient communities are clear about what matters most to them, roughly 90 percent want access to information about their participation in the study including updates about the outcome of a study,” said Cynthia Verst, president, Design and Delivery Innovation, Research & Development Solutions at IQVIA.
Trial participants are invited to join the IQVIA Patient Portal when they are recruited. Upon enrollment, they are guided through the trial process with study visit and medication reminders, disease education, and concierge and travel support services. In addition, they are provided access to the individual lab results from their participation and other general information relating to the study as approved by the sponsor and investigator. Upon trial completion, patients receive a plain language summary of the study. Additionally, patients can join an alumni community where they can continue to engage with clinical research through future trial participation opportunities.
IQVIA’s geographic scale addresses the regulatory and compliance needs of customers regardless of where the study takes place, and retention solutions are built specifically for each clinical trial location with relevant study-level content.
The IQVIA Patient Portal is part of IQVIA’s full-service clinical trial offering or as a stand-alone solution.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
